Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer

Inclusion Criteria: * ≥ 18 and ≤75 years old on day of signing informed consent * Signing informed consent * Patients with histologically confirmed muscle-invasive bladder cancer (cT2-T4, N0, M0) and with strong intent to bladder sparing(Patients with mixed histology, predominantly transitional cells, could be enrolled. ) * Patients must be willing to provide a TURBT specimen during screening and prior to enrollment if adequate specimen (FFPE tissue block or 15 unstained slides) from initial TURBT documenting muscle-invasive urothelial bladder cancer is not available. * ECOG performance status of 0 or 1 * Adequate organ and marrow function for cisplatin treatment * No received prior therapy with systemic chemotherapy or immunotherapy Exclusion Criteria: * Received prior therapies targeting PD-1, PD-L1, PD-L2, CTLA4, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways * Any approved anticancer therapy within 28 days before enrollment * Active leptomeningeal disease or uncontrolled, untreated brain metastasis * Participants with uncontrolled hypercalcemia * Participants with active autoimmune diseases or history of autoimmune diseases that may relapse * History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled diseases * A known history of HIV infection * Prior allogeneic stem cell transplantation or organ transplantation * History of severe hypersensitivity reactions to other monoclonal antibodies * History of allergic reactions to cisplatin, carboplatin, or other platinum-containing compounds